News

Phyllis George, trailblazing sportscaster and former Miss America, is dead at 70 from PV

Phyllis lived a rich and interesting life

The MPN Research Foundation Celebrates It's 2nd Annual Founder's Day

On May 6th, MPNRF will celebrate our 2nd annual Founder's Day in memory of Robert (Bob) Rosen, the person who founded the MPN Research Foundation 20 years ago.

MPNRF Changes Coming

Michelle Woehrle, Steps Down as Executive Director but Continues Fighting for MPN Community

CURE Talks Cancer Hosts MPN Patient-Doctor Duo

CURE Talks Cancer welcomed doctor-patient duo Dr. Ruben A. Mesa and ET patient Antje Hjerpe

MPN and COVID-19 Twitter Chat

Join the chat using the hashtag #MPNandCOVID19!

Your Spring 2020 Newsletter is Here!

Your copy of the Spring 2020 Newsletter from the MPN Research Foundation is now available

MPNRF Newsletter Survey

With this survey, MPNRF wants to learn more about what kind of information you want to see from us and how you want to receive it.

MPN Patients and COVID-19

Dr. Robyn Scherber answers questions she's received from patients regarding Covid-19 or Coronavirus.

Dr. Mesa offers guidance to MPN Patients about the Coronavirus

Dr. Ruben Mesa, Director, Mays Cancer Center, UT Health San Antonio, MD Anderson, offers guidance for patients with MPNs in dealing with the Covid-19

Corona virus and Interferon

There is no current data about the forms of Interferon taken by those with MPN has an impact on Corona Virus. Please consult your doctor with any questions.

CTI Biopharma Granted Fast Track Designation for Pacritinib in the treatment of Myelofibrosis

CTI Biopharma has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the development of Pacritinib in the treatment of Myelofibrosis.

MPNs Update - Spring 2020

Dr. Ruben Mesa and Dr. Robyn Scherber hematologists from the Mays Cancer Center discuss the latest updates in new treatments for MPNs

Imago BioSciences Granted Fast Track Designation for IMG-7289 in Essential Thrombocythemia

Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of Essential Thrombocythemia.